Sleeping apnea syndrome (SAS) in acromegaly and obesity

Daniela Amzar; Stefan Mihaicuta; Ioana Golu; Melania Balas; Ioana Zosin

P590

Prev Next

Section Contents Cite

Endocrine Abstracts (2010) 22 P590

ECE2010 Poster Presentations Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) (125 abstracts)

Sleeping apnea syndrome (SAS) in acromegaly and obesity

Daniela Amzar ¹ , Stefan Mihaicuta ² , Ioana Golu ¹ , Melania Balas ¹ & Ioana Zosin ¹

Err

Author affiliations

¹Department of Endocrinology, University of Medicine and Pharmacy V. Babes, Timisoara, Romania; ²Clinic of Pneumology, University of Medicine and Pharmacy V. Babes, Timisoara, Romania.

The aim of the study: Acromegaly is associated with respiratory and cardiovascular morbidities and high mortality rate. The present study evaluates clinical aspects in acromegalic and obese patients with sleep apnea syndrome (SAS).

Material and method: The patients were diagnosed and followed-up in the Clinic of Endocrinology, Timisoara, in the period 2006–2009. All the cases were confirmed and investigated as present guidelines recommend. The polysomnographic investigated study group comprised 19 acromegalic patients and 13 obese subjects (BMI=42.6 kg/m²).

Results: The prevalence SAS in acromegaly group was 47.3% (9 out of 19 patients). The median of minimum GH level during OGTT was 8.9 ng/ml in apnea group and 5.3 ng/ml in nonapneic group (P>0.05). The mean age was 50±11.8 years (95%CI 40.95–59.05), the neck circumference was 40.33±3.84 cm (95%CI 37.38–43.29), the BMI was 34.66±5.77 kg/m² and the waist circumference was 105.11±10.6 cm (95% CI 96.94–113.3). A percent of 77.7% presented intense snoring, Epworth score 7.55±4.16 (2–15) (95%CI 4.36–10.75). 47.3% presented SAS (12.5%- mild, 37.5%-moderate, 50%-severe form). The mean saturation was 94.77±1.20% (93–97%) (95% CI 93.85–95.70), the desaturation index was 8.22±6.78 per hour (95% CI 3.01–3.43) and the lowest desaturation was 85.22±5.29% (76–93%) (95%CI 81.16–89.29). CPAP was performed in only one patient, with normalization of the hypopnea-apnea index. Five cases presented stage II and III essential hypertension, pulse rate 78.4±14.1 beats/min (62–110) (CI 95% 68.29–88.51) and one case was diagnosed with coronary artery disease. SAS in obesity group was present in 3 out of 13 patients (23.7%).

Conclusion: The study confirms the high prevalence of SAS in acromegaly; half of the acromegaly cases showed severe forms of sleep apnea, with high cardiovascular impact, with daily somnolence, despite the fact that they are snoring and have quite normal neck circumference. GH serum level is not an indicator for the presence and severity of sleep apnea.